Suven Pharmaceuticals Limited has executed definitive agreements today, i.e. on June 13, 2024, for acquiring 100% of equity shares (on a fully diluted basis) (Proposed Transaction) in Sapala Organics Private Limited. Target is a Hyderabad based CDMO focused on Oligo drugs and nucleic acid building blocks including Phosphoramidites & Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others. The Proposed Transaction is subject to customary closing conditions.
Company has agreed to initially acquire 67.5% by way of secondary transfer from Target’s existing shareholders. This represents 51% of the share capital of the Target on a fully diluted basis. After financial year 2026-27, the Company will acquire the balance shareholding through secondary purchase, such that, post consummation, the Company will own 100% of the share capital of the Target on a fully diluted basis.
Suven Pharmaceuticals Limited, one of India’s largest integrated CDMO players, has entered into a definitive agreement for a strategic controlling investment in Sapala Organics Private Limited (“Sapala”), subject to regulatory approvals and conditions.
Sapala is a Hyderabad based CDMO focused on Oligo drugs and nucleic acid building blocks including specialized/modified Amidites & Nucleosides, drug delivery compounds (including GalNAc), Pseudouridine, amongst others. Oligo & nucleic acid building blocks market is a ~$750M market and is expected to grow at a robust ~20% CAGR. Sapala is one of the very few players globally with experience in a comprehensive range of specialized building blocks. Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies, and is a key partner in their Oligo drug NCE programs.
Sapala was founded by Dr P Yella Reddy who has extensive experience in nucleic acid chemistry and formerly worked as Director (R&D) with Aisin Cosmos R&D Co. Ltd (Toyota Group) in Japan & India for 20+ years.
